Pfizer-Seagen innovation theory of harm would be difficult for FTC to prove in court
Pfizer and Seagen have said antitrust regulators have a lot of questions about whether innovation will be maintained after their deal. But while the companies didn’t indicate which jurisdiction is focused...
Subscription required to view this article.
This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: